GlaxoSmithKline Pakistan Limited (PSX:GLAXO)
Pakistan · Delayed Price · Currency is PKR 413.42
-2.15 (-0.52%)
At close: Feb 13, 2026
GlaxoSmithKline Pakistan Income Statement
Financials in millions PKR. Fiscal year is January - December.
Millions PKR. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| 62,074 | 61,188 | 49,661 | 41,842 | 36,661 | 35,090 | |
Revenue Growth (YoY) | 10.39% | 23.21% | 18.69% | 14.13% | 4.48% | -4.08% |
Cost of Revenue | 40,429 | 45,916 | 46,245 | 34,505 | 26,787 | 27,351 |
Gross Profit | 21,646 | 15,271 | 3,416 | 7,336 | 9,874 | 7,739 |
Selling, General & Admin | 7,187 | 6,374 | 6,528 | 5,139 | 3,857 | 4,064 |
Other Operating Expenses | -459.58 | -1,355 | -5,077 | -2,871 | -856 | -1,234 |
Operating Expenses | 6,727 | 5,019 | 1,451 | 2,268 | 3,001 | 2,830 |
Operating Income | 14,918 | 10,252 | 1,965 | 5,068 | 6,873 | 4,909 |
Interest Expense | - | -19.28 | -6.52 | -5.37 | -5.43 | -6.5 |
Interest & Investment Income | 525.66 | 538.91 | 277.02 | 829.54 | 374.94 | 235.53 |
Currency Exchange Gain (Loss) | -221.11 | -221.11 | 68.24 | -703.51 | -156.49 | -75.86 |
Other Non Operating Income (Expenses) | -72.38 | -72.38 | -56.48 | -7.37 | -2.52 | -1.75 |
EBT Excluding Unusual Items | 15,151 | 10,478 | 2,247 | 5,182 | 7,084 | 5,061 |
Merger & Restructuring Charges | -5.61 | -5.61 | -215.25 | -146.51 | -321.57 | -158.17 |
Gain (Loss) on Sale of Assets | 54.51 | 21.88 | 82.76 | 124.62 | 633.9 | 17.21 |
Asset Writedown | -18.39 | -18.39 | -6.01 | -54.02 | -15.54 | -80.81 |
Other Unusual Items | - | - | 68.56 | - | 43.88 | 63.87 |
Pretax Income | 15,181 | 10,476 | 2,177 | 5,106 | 7,424 | 4,903 |
Income Tax Expense | 5,994 | 3,940 | 1,643 | 2,643 | 2,070 | 1,527 |
Earnings From Continuing Operations | 9,187 | 6,536 | 533.95 | 2,463 | 5,354 | 3,375 |
Net Income | 9,187 | 6,536 | 533.95 | 2,463 | 5,354 | 3,375 |
Net Income to Common | 9,187 | 6,536 | 533.95 | 2,463 | 5,354 | 3,375 |
Net Income Growth | 103.85% | 1124.09% | -78.32% | -54.00% | 58.64% | 10.99% |
Shares Outstanding (Basic) | 318 | 318 | 318 | 318 | 318 | 318 |
Shares Outstanding (Diluted) | 318 | 318 | 318 | 318 | 318 | 318 |
EPS (Basic) | 28.85 | 20.52 | 1.68 | 7.73 | 16.81 | 10.60 |
EPS (Diluted) | 28.85 | 20.52 | 1.68 | 7.73 | 16.81 | 10.60 |
EPS Growth | 103.85% | 1124.09% | -78.32% | -54.00% | 58.64% | 10.99% |
Free Cash Flow | 4,377 | 2,282 | 234.56 | -4,694 | 3,683 | 4,644 |
Free Cash Flow Per Share | 13.74 | 7.17 | 0.74 | -14.74 | 11.57 | 14.58 |
Dividend Per Share | 15.000 | 10.000 | - | - | 7.000 | 6.500 |
Dividend Growth | - | - | - | - | 7.69% | 8.33% |
Gross Margin | 34.87% | 24.96% | 6.88% | 17.53% | 26.93% | 22.05% |
Operating Margin | 24.03% | 16.75% | 3.96% | 12.11% | 18.75% | 13.99% |
Profit Margin | 14.80% | 10.68% | 1.07% | 5.89% | 14.61% | 9.62% |
Free Cash Flow Margin | 7.05% | 3.73% | 0.47% | -11.22% | 10.05% | 13.23% |
EBITDA | 16,184 | 11,344 | 2,881 | 5,910 | 7,634 | 5,658 |
EBITDA Margin | 26.07% | 18.54% | 5.80% | 14.12% | 20.82% | 16.12% |
D&A For EBITDA | 1,266 | 1,093 | 916.48 | 841.69 | 760.47 | 748.68 |
EBIT | 14,918 | 10,252 | 1,965 | 5,068 | 6,873 | 4,909 |
EBIT Margin | 24.03% | 16.75% | 3.96% | 12.11% | 18.75% | 13.99% |
Effective Tax Rate | 39.48% | 37.61% | 75.48% | 51.76% | 27.88% | 31.16% |
Advertising Expenses | - | 24.37 | 22.89 | - | - | - |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.